1427-06-1 Usage
General Description
6-Fluoronicotinic acid methyl ester is a chemical compound that belongs to the class of fluorinated organic compounds. It is derived from nicotinic acid and contains a methyl ester functional group. 6-FLUORONICOTINIC ACID METHYL ESTER has potential applications in the field of organic synthesis and pharmaceuticals. It is commonly used as a building block in the synthesis of various pharmaceutical ingredients and agrochemicals. It is also used as a precursor in the production of fluorinated derivatives of nicotinamide, which have been studied for their potential biological activities. Overall, 6-fluoronicotinic acid methyl ester is an important intermediate compound with versatile applications in chemical and pharmaceutical industries.
Check Digit Verification of cas no
The CAS Registry Mumber 1427-06-1 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 1,4,2 and 7 respectively; the second part has 2 digits, 0 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1427-06:
(6*1)+(5*4)+(4*2)+(3*7)+(2*0)+(1*6)=61
61 % 10 = 1
So 1427-06-1 is a valid CAS Registry Number.
InChI:InChI=1/C7H6FNO2/c1-11-7(10)5-2-3-6(8)9-4-5/h2-4H,1H3
1427-06-1Relevant articles and documents
Glucagon Receptor Modulators
-
Page/Page column 67, (2012/07/13)
The present invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof wherein R1, R2, R3, A1, A2, A3, A4, L, B1, B2, B3 and B4 are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.
BENZOTRIAZEPINONE DERIVATIVES
-
Page/Page column 69, (2010/11/29)
The present invention is concerned with benzotriazepinone derivatives, their intermediates, uses thereof and processes for their production. In particular, the present invention relates to parathyroid hormone (PTH) and parathyroid hormone related protein (PTHrp) receptor ligands, (PTH-1 or PTH/PTHrp receptor ligands). The invention also relates to methods of preparing such ligands and to compounds which are useful as intermediates in such methods.